Rubella (German Measles) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 44 Published: October 31, 2021 Report Code: GMDGDHC13111IDB

The Rubella (German Measles) drugs in development market report provides comprehensive information on the therapeutics under development for Rubella (German Measles), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects.

What are the key RoA in the rubella drugs in development market?

The key RoA in the rubella drugs in development market are Subcutaneous, and Intradermal. Among them Subcutaneous has the highest number of products.

Rubella drugs in development market, by RoA

Rubella drugs in development market, by RoA

For more RoA insights, download a free sample

What are the key molecule types in the rubella drugs in development market?

The key molecule types in the rubella drugs in development market are Vaccine and Live Attenuated Vaccine. Among them Vaccine has the highest number of products.

Rubella drugs in development market, by molecule type

Rubella drugs in development market, by molecule type

For more molecule type insights, download a free sample

Which are the key companies in the rubella drugs in development market?

The key companies in the rubella drugs in development market are Beijing Minhai Biotechnology Co Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Co Ltd, Enesi Pharma Ltd, GlaxoSmithKline Plc, Indian Immunologicals Ltd, Micron Biomedical Inc, Sinovac Biotech Ltd, Univercells SA, Vaxxas Inc, and Zhongyianke Biotech Co Ltd. Beijing Minhai Biotechnology Co Ltd had the highest number of products in the rubella drugs in development market.

Rubella drugs in development market, by companies

Rubella drugs in development market, by companies

To know more about key companies, download a free sample

Market report scope

Key RoA Subcutaneous, and Intradermal
Key molecule type Vaccine and Live Attenuated Vaccine
Key companies Beijing Minhai Biotechnology Co Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Co Ltd, Enesi Pharma Ltd, GlaxoSmithKline Plc, Indian Immunologicals Ltd, Micron Biomedical Inc, Sinovac Biotech Ltd, Univercells SA, Vaxxas Inc, and Zhongyianke Biotech Co Ltd.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rubella (German Measles) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Rubella (German Measles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rubella (German Measles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rubella (German Measles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rubella (German Measles) (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rubella (German Measles) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rubella (German Measles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

  • Beijing Minhai Biotechnology Co Ltd

    Cadila Healthcare Ltd

    Daiichi Sankyo Co Ltd

    Enesi Pharma Ltd

    GlaxoSmithKline Plc

    Indian Immunologicals Ltd

    Micron Biomedical Inc

    Sinovac Biotech Ltd

    Univercells SA

    Vaxxas Inc

    Zhongyianke Biotech Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Rubella (German Measles) – Overview

Rubella (German Measles) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Rubella (German Measles) – Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Rubella (German Measles) – Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Cadila Healthcare Ltd

Daiichi Sankyo Co Ltd

Enesi Pharma Ltd

GlaxoSmithKline Plc

Indian Immunologicals Ltd

Micron Biomedical Inc

Sinovac Biotech Ltd

Univercells SA

Vaxxas Inc

Zhongyianke Biotech Co Ltd

Rubella (German Measles) – Drug Profiles

(measles + mumps + rubella + varicella) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + mumps + rubella + varicella) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + mumps + rubella) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + mumps + rubella) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + rubella) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + rubella) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + rubella) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + rubella) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + rubella) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BK-1601 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rubella vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VN-0102 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rubella (German Measles) – Dormant Projects

Rubella (German Measles) – Product Development Milestones

Featured News & Press Releases

Aug 02, 2021: GSK files for licensure of MMR vaccine in the US

May 05, 2021: Enesi Pharma achieves key milestone in development of thermostable solid-dose live vaccines against measles and rubella

Mar 18, 2020: Vaxxas awarded US$5 million grant for clinical study of measles and rubella vaccination

Nov 30, 2019: Vaxxas was awarded research and development fund of USD 4,997,693 from Bill & Melinda Gates Foundation

Nov 30, 2016: Vaxxas was awarded research and development fund of USD 4,479,552 from Bill & Melinda Gates Foundation

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Rubella (German Measles), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Rubella (German Measles) – Pipeline by Beijing Minhai Biotechnology Co Ltd, 2021

Rubella (German Measles) – Pipeline by Cadila Healthcare Ltd, 2021

Rubella (German Measles) – Pipeline by Daiichi Sankyo Co Ltd, 2021

Rubella (German Measles) – Pipeline by Enesi Pharma Ltd, 2021

Rubella (German Measles) – Pipeline by GlaxoSmithKline Plc, 2021

Rubella (German Measles) – Pipeline by Indian Immunologicals Ltd, 2021

Rubella (German Measles) – Pipeline by Micron Biomedical Inc, 2021

Rubella (German Measles) – Pipeline by Sinovac Biotech Ltd, 2021

Rubella (German Measles) – Pipeline by Univercells SA, 2021

Rubella (German Measles) – Pipeline by Vaxxas Inc, 2021

Rubella (German Measles) – Pipeline by Zhongyianke Biotech Co Ltd, 2021

Rubella (German Measles) – Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development for Rubella (German Measles), 2021

Number of Products under Development by Companies, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.